Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

July 30, 2013; 81 (5) Special Article

Evidence-based guideline: Treatment of tardive syndromes

Report of the Guideline Development Subcommittee of the American Academy of Neurology

Roongroj Bhidayasiri, Stanley Fahn, William J. Weiner, Gary S. Gronseth, Kelly L. Sullivan, Theresa A. Zesiewicz
First published July 29, 2013, DOI: https://doi.org/10.1212/WNL.0b013e31829d86b6
Roongroj Bhidayasiri
From the Chulalongkorn Parkinson's Disease and Related Disorders Center of Excellence, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society (R.B.), Bangkok, Thailand; Department of Neurology (R.B.), David Geffen School of Medicine at UCLA, Los Angeles, CA; Department of Neurology (S.F.), Columbia University, New York, NY; Department of Neurology (W.J.W.), University of Maryland, Baltimore, MD; Department of Neurology (G.S.G.), University of Kansas Medical Center, Kansas City, KS; and Department of Neurology (K.L.S., T.A.Z.), University of South Florida, Tampa, FL.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stanley Fahn
From the Chulalongkorn Parkinson's Disease and Related Disorders Center of Excellence, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society (R.B.), Bangkok, Thailand; Department of Neurology (R.B.), David Geffen School of Medicine at UCLA, Los Angeles, CA; Department of Neurology (S.F.), Columbia University, New York, NY; Department of Neurology (W.J.W.), University of Maryland, Baltimore, MD; Department of Neurology (G.S.G.), University of Kansas Medical Center, Kansas City, KS; and Department of Neurology (K.L.S., T.A.Z.), University of South Florida, Tampa, FL.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William J. Weiner
From the Chulalongkorn Parkinson's Disease and Related Disorders Center of Excellence, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society (R.B.), Bangkok, Thailand; Department of Neurology (R.B.), David Geffen School of Medicine at UCLA, Los Angeles, CA; Department of Neurology (S.F.), Columbia University, New York, NY; Department of Neurology (W.J.W.), University of Maryland, Baltimore, MD; Department of Neurology (G.S.G.), University of Kansas Medical Center, Kansas City, KS; and Department of Neurology (K.L.S., T.A.Z.), University of South Florida, Tampa, FL.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gary S. Gronseth
From the Chulalongkorn Parkinson's Disease and Related Disorders Center of Excellence, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society (R.B.), Bangkok, Thailand; Department of Neurology (R.B.), David Geffen School of Medicine at UCLA, Los Angeles, CA; Department of Neurology (S.F.), Columbia University, New York, NY; Department of Neurology (W.J.W.), University of Maryland, Baltimore, MD; Department of Neurology (G.S.G.), University of Kansas Medical Center, Kansas City, KS; and Department of Neurology (K.L.S., T.A.Z.), University of South Florida, Tampa, FL.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kelly L. Sullivan
From the Chulalongkorn Parkinson's Disease and Related Disorders Center of Excellence, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society (R.B.), Bangkok, Thailand; Department of Neurology (R.B.), David Geffen School of Medicine at UCLA, Los Angeles, CA; Department of Neurology (S.F.), Columbia University, New York, NY; Department of Neurology (W.J.W.), University of Maryland, Baltimore, MD; Department of Neurology (G.S.G.), University of Kansas Medical Center, Kansas City, KS; and Department of Neurology (K.L.S., T.A.Z.), University of South Florida, Tampa, FL.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Theresa A. Zesiewicz
From the Chulalongkorn Parkinson's Disease and Related Disorders Center of Excellence, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society (R.B.), Bangkok, Thailand; Department of Neurology (R.B.), David Geffen School of Medicine at UCLA, Los Angeles, CA; Department of Neurology (S.F.), Columbia University, New York, NY; Department of Neurology (W.J.W.), University of Maryland, Baltimore, MD; Department of Neurology (G.S.G.), University of Kansas Medical Center, Kansas City, KS; and Department of Neurology (K.L.S., T.A.Z.), University of South Florida, Tampa, FL.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Evidence-based guideline: Treatment of tardive syndromes
Report of the Guideline Development Subcommittee of the American Academy of Neurology
Roongroj Bhidayasiri, Stanley Fahn, William J. Weiner, Gary S. Gronseth, Kelly L. Sullivan, Theresa A. Zesiewicz
Neurology Jul 2013, 81 (5) 463-469; DOI: 10.1212/WNL.0b013e31829d86b6

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
12762

Share

This article has a correction. Please see:

  • Evidence-based guideline: Treatment of tardive syndromes: Report of the Guideline Development Subcommittee of the American Academy of Neurology - November 26, 2013
  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

Objective: To make evidence-based recommendations regarding management of tardive syndromes (TDS), including tardive dyskinesias (TDD), by addressing 5 questions: 1) Is withdrawal of dopamine receptor blocking agents (DRBAs) an effective TDS treatment? 2) Does switching from typical to atypical DRBAs reduce TDS symptoms? 3) What is the efficacy of pharmacologic agents in treating TDS? 4) Do patients with TDS benefit from chemodenervation with botulinum toxin? 5) Do patients with TDS benefit from surgical therapy?

Methods: PsycINFO, Ovid MEDLINE, EMBASE, Web of Science, and Cochrane were searched (1966–2011). Articles were classified according to a 4-tiered evidence-rating scheme; recommendations were tied to the evidence.

Results and recommendations: Clonazepam probably improves TDD and ginkgo biloba probably improves TDS (both Level B); both should be considered as treatment. Risperidone may improve TDS but cannot be recommended as treatment because neuroleptics may cause TDS despite masking symptoms. Amantadine and tetrabenazine might be considered as TDS treatment (Level C). Diltiazem should not be considered as TDD treatment (Level B); galantamine and eicosapentaenoic acid may not be considered as treatment (Level C). Data are insufficient to support or refute use of acetazolamide, bromocriptine, thiamine, baclofen, vitamin E, vitamin B6, selegiline, clozapine, olanzapine, melatonin, nifedipine, fluperlapine, sulpiride, flupenthixol, thiopropazate, haloperidol, levetiracetam, quetiapine, ziprasidone, sertindole, aripiprazole, buspirone, yi-gan san, biperiden discontinuation, botulinum toxin type A, electroconvulsive therapy, α-methyldopa, reserpine, and pallidal deep brain stimulation as TDS treatments (Level U). Data are insufficient to support or refute TDS treatment by withdrawing causative agents or switching from typical to atypical DRBA (Level U).

GLOSSARY

AAN=
American Academy of Neurology;
AIMS=
Abnormal Involuntary Movement Scale;
BoNT=
botulinum toxin;
DBS=
deep brain stimulation;
DRBA=
dopamine receptor blocking agent;
EPA=
eicosapentaenoic acid;
GABA=
γ-aminobutyric acid;
RCT=
randomized controlled trial;
TBZ=
tetrabenazine;
TD=
tardive dystonia;
TDD=
tardive dyskinesia;
TDS=
tardive syndrome

Footnotes

  • ↵† Deceased.

  • Approved by the Guideline Development Subcommittee on January 21, 2012; by the Practice Committee on October 1, 2012; and by the AAN Board of Directors on April 25, 2013.

  • Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

  • Supplemental data at www.neurology.org

  • Received October 5, 2012.
  • Accepted in final form April 22, 2013.
  • © 2013 American Academy of Neurology
View Full Text

Disputes & Debates: Rapid online correspondence

  • Reply from the guideline authors
    • Roongroj Bhidayasiri, Director and Associate Professor of Neurology, Chulalongkorn University, Department of Medicine, Bangkok, Thailandguidelines@aan.com
    • Stanley Fahn, New York, NY; Gary S. Gronseth, Kansas City, KS; Kelly L. Sullivan, Tampa, FL; Theresa A. Zesiewicz, Tampa, FL
    Submitted September 04, 2013
  • Evidence-based guideline: Treatment of tardive syndromes Report of the Guideline Development Subcommittee of the American Academy of Neurology
    • Vladimir Lerner, Director of psychiatric ward, Ben Gurion University of the Negev, Be'er Sheva, Israellernervld@yahoo.com
    • Chanoch Miodownik, Vladimir Lerner, Be'er Sheva, Israel
    Submitted August 21, 2013
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • GLOSSARY
    • DESCRIPTION OF THE ANALYTIC PROCESS
    • ANALYSIS OF EVIDENCE
    • RECOMMENDATIONS FOR FUTURE RESEARCH
    • AUTHOR CONTRIBUTIONS
    • STUDY FUNDING
    • DISCLOSURE
    • DISCLAIMER
    • CONFLICT OF INTEREST
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Disclosures
Advertisement

Related Articles

  • Evidence-based guideline: Treatment of tardive syndromes: Report of the Guideline Development Subcommittee of the American Academy of Neurology

Topics Discussed

  • All Movement Disorders

Alert Me

  • Alert me when eletters are published
Neurology: 96 (9)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise